Clinical Trials Logo

Clinical Trial Summary

The investigators hypothecate that pentoxyfilline increase significantly the liver regeneration and reduces significantly ischemia and reperfusion (I/R) injury in major liver using aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as marker of I/R injury.


Clinical Trial Description

Liver resection is for many patients with primary or secondary hepatic malignancies the only curative treatment option. Often, the complete clearance of the hepatic tumor disease can be only achieved by extended liver resections. Clinical studies have demonstrated that intra-operative blood loss is associated reduced outcome after major liver resection. An effective strategy to reduce blood loss is the occlusion of the portal triad (Pringle manoeuvre). On the other hand, inflow occlusion results in ischemia- and reperfusion (I/R) injury. Randomized trials have shown that ischemic preconditioning (10 min clamping, 10 min reperfusion) and intermittent clamping (15 min clamping, 5 min reperfusion) result in reduction of the I/R injury. Another potential strategy to reduce I/R injury is the pharmacological protection. One promising drug is pentoxyfilline (PTF) which has vasodilative and hemorheologic effects. Furthermore, PTF suppresses the TNF release. These effects may be also protective in major liver resection under inflow occlusion (Pringle manoeuvre)and increase the liver regeneration. Therefore, we designed a randomised prospective trial to investigate the effects of PTF treatment in liver resection under inflow occlusion. The specific aims of the research project are:The investigators hypothecate that pentoxyfilline increases significantly the liver regeneration and reduces significantly ischemia and reperfusion (I/R) injury in liver using aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as marker of I/R injury. ;


Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00957619
Study type Interventional
Source University of Zurich
Contact
Status Completed
Phase Phase 4
Start date March 2006
Completion date January 2010

See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Recruiting NCT04178759 - Impact of Chemotherapy and Regenerative Markers of Liver Regeneration After Liver Resection for Liver Metastases N/A
Not yet recruiting NCT06091787 - Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy N/A
Completed NCT04565535 - Effect of Novel Donor Lifestyle Optimisation Protocol on Liver Regeneration in Live Liver Donors N/A
Recruiting NCT06126419 - Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration N/A
Recruiting NCT02113059 - Platelets in Liver Regeneration N/A
Completed NCT02945059 - Reversible Portal Vein Embolization Before Major Hepatectomy N/A
Recruiting NCT04107324 - ARAPS Study on Accelerated Liver Regeneration N/A
Completed NCT05459883 - Splenic Artery Ligation and Portocaval Shunt in Small-for-size Syndrome
Recruiting NCT02327832 - Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs Phase 1
Enrolling by invitation NCT01924741 - Registry of Major Liver Resections Including ALPPS and Other Liver Resections in Two Stages N/A